<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05618418</url>
  </required_header>
  <id_info>
    <org_study_id>H-21041462</org_study_id>
    <nct_id>NCT05618418</nct_id>
  </id_info>
  <brief_title>BActeriophages To Treat Liver Disease Eliminating Harmful Bacteria (BATTLE)</brief_title>
  <acronym>BATTLE</acronym>
  <official_title>BActeriophages To Treat Liver Disease Eliminating Harmful Bacteria (BATTLE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Copenhagen University Hospital, Hvidovre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Copenhagen University Hospital at Herlev</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Copenhagen University Hospital, Hvidovre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alcoholic hepatitis is a disease with a high mortality rate with few treatment options&#xD;
      improving survival. Recently certain bacterial strains has been correlated to survival in&#xD;
      patients with alcoholic hepatitis.&#xD;
&#xD;
      In the BATTLE-trial the investigators will investigate if certain bacteria are correlated to&#xD;
      decreased chance of survival in patients with alcoholic hepatitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with alcoholic hepatitis who are admitted to Copenhagen University Hospital Hvidovre&#xD;
      and Herlev will be invited to participate.&#xD;
&#xD;
      Blood and fecal samples following hospital admission will be collected. Through one-year&#xD;
      follow-up correlation of certain bacteria in fecal samples with survival will be&#xD;
      investigated.&#xD;
&#xD;
      In particular whether patients with cytolysin producing E. faecalis has a decreased chance of&#xD;
      survival compared to patients without this bacteria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2022</start_date>
  <completion_date type="Anticipated">January 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Survival in patients with and without cytolysin producing E. faecalis in fecal samples</measure>
    <time_frame>6 months</time_frame>
    <description>Patient alive/not alive - Cytolysin producing E. faecalis in fecal samples from hospital admission (yes/no)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival in patients with and without cytolysin producing E. faecalis in fecal samples</measure>
    <time_frame>1 year</time_frame>
    <description>Patient alive/not alive - Cytolysin producing E. faecalis in fecal samples from hospital admission (yes/no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival in patients with and without cytolysin producing E. faecalis in fecal samples</measure>
    <time_frame>30 days</time_frame>
    <description>Patient alive/not alive - Cytolysin producing E. faecalis in fecal samples from hospital admission (yes/no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival in patients with and without cytolysin producing E. faecalis in fecal samples</measure>
    <time_frame>90 days</time_frame>
    <description>Patient alive/not alive - Cytolysin producing E. faecalis in fecal samples from hospital admission (yes/no)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Alcoholic Hepatitis</condition>
  <arm_group>
    <arm_group_label>Hospital admitted patients with alcoholic hepatitis</arm_group_label>
    <description>Inclusion criteria:&#xD;
Age ≥ 18 Bilirubin &gt; 50 micromol/L History of large alcoholic consumption in period prior to hospital admission (in the last six months) No bile-duct obstruction (investigated through US, CT og MRI)&#xD;
Exclusion criteria:&#xD;
Hepatocellulary carcinoma Viral hepatitis Autoimmune hepatitis Portal thrombosis Pregnancy Expected survival for less than one year caused by other diseases (based on decision from project responsible doctors)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention</description>
    <arm_group_label>Hospital admitted patients with alcoholic hepatitis</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Fecal samples collected&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hospital admitted patients with alcoholic hepatitis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18&#xD;
&#xD;
          -  Bilirubin &gt; 50 micromol/L&#xD;
&#xD;
          -  History of large alcoholic consumption in period prior to hospital admission (in the&#xD;
             last six months)&#xD;
&#xD;
          -  No bile-duct obstruction (investigated through US, CT og MRI)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hepatocellulary carcinoma&#xD;
&#xD;
          -  Viral hepatitis&#xD;
&#xD;
          -  Autoimmune hepatitis&#xD;
&#xD;
          -  Portal vein thrombosis&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Expected survival for less than one year caused by other diseases (based on decision&#xD;
             from project responsible doctors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>frederik cold, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Copenhagen University Hospital, Hvidovre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>frederik cold, MD, PHD</last_name>
    <phone>+4521157167</phone>
    <email>frederik.cold@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Copenhagen University Hospital Hvidovre</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>frederik cold, MD, PHD</last_name>
      <phone>21157167</phone>
      <email>frederik.cold@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 3, 2022</study_first_submitted>
  <study_first_submitted_qc>November 10, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2022</study_first_posted>
  <last_update_submitted>November 10, 2022</last_update_submitted>
  <last_update_submitted_qc>November 10, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Copenhagen University Hospital, Hvidovre</investigator_affiliation>
    <investigator_full_name>Frederik Cold</investigator_full_name>
    <investigator_title>Principal Investigator, MD, Ph.d., Specialist Registrar in Medical Gastroenterology</investigator_title>
  </responsible_party>
  <keyword>Gut microbiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to make data available to researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

